United States of America

Below are links to copies of the contracts entered into by the US government for technologies to combat the COVID-19 pandemic. KEI is updating this page as we gain access to more contracts, and less redacted versions.

KEI has also created a US COVID-19 contract spreadsheet to track metadata of the agreements, as well as to compare the terms contained therein for intellectual property rights, data, and other topics. (Note: At this time, this spreadsheet is being continually updated.)

Department of Health and Human Services (HHS)

Biomedical Advanced Research and Development Authority (BARDA)

• AstraZeneca – vaccine.
  • HHS/ASPR/BARDA-AstraZeneca Advanced Agreement to Other Transaction Authority Agreement 75A501-20-C-00114. May 20, 2020.
  • HHS/ASPR/BARDA-AstraZeneca Modification of OTA Agreement 75A501-20-C-00114 MODP00001. July 31, 2020.
• Johnson&Johnson (Janssen) – vaccine.
  • HHS/ASPR/BARDA-Janssen Other Transaction Authority Agreement HHSO100201700018C (FOIA records did not include original agreement).
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 6. February 11, 2020.
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 7. March 20, 2020.
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201700018C-Amendment 8. March 27, 2020.
• Moderna – vaccine.
  • HHS/ASPR/BARDA-Moderna Contract 75A50120C00034. April 16, 2020.
• Protein Sciences Corporation (Sanofi) – vaccine.
  • HHS-ASPR/BARDA-Protein Sciences Corp Contract HHSO100201600005I. February 14, 2020.
• Johnson&Johnson (Janssen) – therapeutic.
  • HHS/ASPR/BARDA-Janssen Other Transaction Authority Agreement HHSO100201800012C. September 21, 2018.
  • HHS/ASPR/BARDA-Janssen Amendment to OTA Agreement HHSO100201800012C-Amendment 4. February 14, 2020.
• Genentech (Roche) -therapeutic.
  • HHS/ASPR/BARDA-Genentech Other Transaction Authority Agreement HHSO100201800036C. September 27, 2018.
  • HHS/ASPR/BARDA-Genentech Modification of OTA Agreement HHSO100201800036C. March 27, 2020.
• Regeneron Pharmaceuticals – therapeutic.
  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C. September 21, 2017.
  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C-MOD(redacted). January 31, 2020.
  • HHS/ASPR/BARDA-Regeneron Other Transaction Authority Agreement HHSO100201700020C-MOD0006. (Date redacted).

Agreements not concerning COVID-19 research, but tied to related vaccine technologies:

• Moderna – Zika vaccine.
  • HHS/ASPR/BARDA-Moderna Contract HHS0100201600029C. September 1, 2016.

Department of Defense

• Ology Bioservices (previously called Nanotherapeutics, Inc.) – vaccine manufacturing.
  • DoD-Ology Bioservices Other Transaction Authority Agreement OTA-W911QY2090003. February 21, 2020.
  • DoD-Ology Bioservices Other Transaction Authority Agreement Appendix OTA-W911QY2090003-Appendix-A-4. March 20, 2020.
  • DoD-Ology Bioservices Contract W911QY2090003-MOD-P00005. March 22, 2020.
• Tasso – antibody test kits.
  • DOD-Tasso Serology Contract W911QY20P0158. May 1, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)

Agreements related to the Medical CBRN Defense Consortium (MCDC) whose agreements are executed by Advanced Technology International (ATI):

• Advanced Technology International (ATI) – Underlying contract to execute MCDC and COVID-19 contracts on behalf of the federal government.
  • DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016.
  • DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
• Johnson&Johnson (Janssen) – vaccine.
  • DoD (via ATI)-Janssen Other Transaction Authority Agreement W15QKN1691002-P00081. August 5, 2020.
• Novavax – vaccine.
  • DoD (via ATI)-Novavax Other Transaction Authority Agreement W15QKN1691002. June 25, 2020.
  • DoD (via ATI)-Novavax Technical Direction Letter W15QKN1691002. July 6, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
• Pfizer – vaccine.
  • DoD (via ATI)-Pfizer Technical Direction Letter OTA W15QKN1691002. July 21, 2020.
• Regeneron – therapeutic manufacturing.
  • DoD (via ATI)-Regeneron Other Transaction Authority Agreement W15QKN1691002. July 6, 2020.
  • DoD (via ATI)-Regeneron Technical Direction Letter W15QKN1691002. July 6, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
• Sanofi – vaccine. 
  • DOD (via ATI)-Sanofi Technical Direction Letter W15QKN1691002. July 30, 2020. (Version obtained November 30, 2020 from HHS FOIA Reading Room)

Joint HHS-DoD Agreements (excluding MCDC)

• Moderna – vaccine manufacturing.
  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained from Moderna SEC filings)
  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained October 29, 2020 from HHS FOIA Reading Room)
  • DoD/ASPR/BARDA-Moderna Contract W911QY20C0100. August 9, 2020. (Version obtained November 9, 2020 from HHS FOIA Reading Room)
• Retractable Technologies, Inc. (RTI) – needle production.
  • DoD/ASPR/BARDA-RTI Contract W911SR2030004. July 1, 2020.
• Becton Dickinson and Company- needle production.
  • DoD/ASPR/BARDA-Becton Dickinson Contract W911SR2030001. July 1, 2020.

Brazil

• Fundação Oswaldo Cruz (Fiocruz) – COVID-19 vaccine.
  • Fiocruz-AstraZeneca Contract. September 8, 2020.